Preemptive adefovir versus lamivudine for prevention of hepatitis B reactivation in chronic hepatitis B patients undergoing chemotherapy

Hepatology International

Volumn 9, Issue 2, 2015, Pages 224-230

  Ho, Edith Y ^a   Yau, Thomas ^b   Rousseau, Franck ^c   Heathcote, E Jenny ^d   Lau, George K K ^e,f  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c Tranzyme Pharma   (United States)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e Humanity and Health GI and Liver Center   (Hong Kong)

^f BEIJING 302 HOSPITAL   (China)

Author keywords

Adefovir; Chemotherapy; Hepatitis B; Hepatitis B reactivation; Lamivudine

Indexed keywords

ADEFOVIR DIPIVOXIL; ADENINE; ANTIVIRUS AGENT; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PHOSPHONIC ACID DERIVATIVE; VIRUS DNA;

ADULT; AGED; ANALOGS AND DERIVATIVES; ANTIVIRAL RESISTANCE; BLOOD; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECTS; FEMALE; GENETICS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMAN; MALE; MIDDLE AGED; MUTATION; NEOPLASMS; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY; VIRUS ACTIVATION; YOUNG ADULT;

ADENINE; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; NEOPLASMS; ORGANOPHOSPHONATES; VIRUS ACTIVATION; YOUNG ADULT;

EID: 84939948235     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-015-9612-6     Document Type: Article

References (51)

1. Hoofnagle JH, et al. Management of hepatitis B: summary of a clinical research workshop. Hepatology. 2007;45(4):1056–1075
2. Cheng AL, et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology. 2003;37(6):1320–1328
3. Lok AS, et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology. 1991;100(1):182–188
4. Loomba R, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med. 2008;148(7):519–528
5. Yeo W, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol. 2000;62(3):299–307
6. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology. 2006;43(2):209–220
7. Yeo W, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2009;27(4):605–611
8. Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol. 2007;136(5):699–712
9. Lau JY, et al. Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients. Q J Med. 1989;73(270):911–917
10. Wands JR, et al. Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology. 1975;68(1):105–112
11. Steinberg JL, et al. Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore/core mutations may play an important role. J Med Virol. 2000;60(3):249–255
12. Yeo W, et al. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol. 2003;70(4):553–561
13. Citron ML, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21(8):1431–1439
14. Bonadonna G, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med. 1995;332(14):901–906
15. Yeo W, et al. Prevention of hepatitis B virus reactivation in patients with nasopharyngeal carcinoma with lamivudine. Am J Clin Oncol. 2005;28(4):379–384
16. Nagamatsu H, et al. Investigation of associating factors in exacerbation of liver damage after chemotherapy in patients with HBV-related HCC. Hepatol Res. 2003;26(4):293–301
17. Nagamatsu H, et al. Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy. Am J Gastroenterol. 2004;99(12):2369–2375
18. Hoofnagle JH, et al. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med. 1982;96(4):447–449
19. Lau GK. Hepatitis B reactivation after chemotherapy: two decades of clinical research. Hepatol Int. 2008;2(2):152–162
20. Lau GK, Lee CK, Liang R. Hepatitis B virus infection and bone marrow transplantation. Crit Rev Oncol Hematol. 1999;31(1):71–76
21. Liang R, Lau GKK, Kwong YL. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J Clin Oncol. 1999;17(1):394
22. Xunrong L, Yan AW, Liang R, Lau GK. Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy: pathogenesis and management. Rev Med Virol. 2001;11(5):287–299
23. Perrillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology. 2001;120(4):1009–1022
24. Xunrong L, et al. Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy: pathogenesis and management. Rev Med Virol. 2001;11(5):287–299
25. Chan TM, et al. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. Hepatology. 2002;36(5):1246–1252
26. Hsu C, et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin’s lymphoma: a randomized trial. Hepatology. 2008;47(3):844–853
27. Kohrt HE, Ouyang DL, Keeffe EB. Antiviral prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Clin Liver Dis. 2007;11(4):965–991
28. Lau GK, et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood. 2002;99(7):2324–2330
29. Lau GKK, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology. 2003;125(6):1742–1749
30. Rossi G, et al. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol. 2001;115(1):58–62
31. Dienstag JL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 1999;341(17):1256–1263
32. Lai CL, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med. 1998;339(2):61–68
33. Schalm SW, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut. 2000;46(4):562–568
34. Chang TT, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol. 2004;19(11):1276–1282
35. Lok AS, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 2003;125(6):1714–1722
36. Loomba R, Liang TJ. Novel approaches to new therapies for hepatitis B virus infection. Antivir Ther. 2006;11(1):1–15
37. Hui CK, Lau GK. Current issues and future directions in treatment. Semin Liver Dis. 2006;26(2):192–197
38. Perez-Roldan F, Gonzalez-Carro P, Villafanez-Garcia MC. Adefovir dipivoxil for chemotherapy-induced activation of hepatitis B virus infection. N Engl J Med. 2005;352(3):310–311
39. Hadziyannis SJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med. 2003;348(9):800–807
40. Marcellin P, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003;348(9):808–816
41. Hadziyannis SJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med. 2005;352(26):2673–2681
42. Hadziyannis SJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006;131(6):1743–1751
43. Tillmann HL. The treatment of chronic hepatitis B: focus on adefovir-like antivirals. Ther Clin Risk Manag. 2008;4(4):797–802
44. Yang H, et al. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther. 2005;10(5):625–633
45. Enomoto M, et al. Adefovir dipivoxil to prevent exacerbation of lamivudine-resistant hepatitis B infection during chemotherapy for non-Hodgkin’s lymphoma. Am J Gastroenterol. 2004;99(8):1619–1620
46. Hui CK, et al. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut. 2005;54(11):1597–1603
47. Mindikoglu AL, Regev A, Schiff ER. Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention. Clin Gastroenterol Hepatol. 2006;4(9):1076–1081
48. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50(3):661–662
49. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45(2):507–539
50. Watanabe M, et al. Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation: a review of 16 patients. Eur J Intern Med. 2010;21(4):333–337
51. Li HR, et al. Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy. J Viral Hepat. 2011;18(12):877–883